Literature DB >> 16792453

Prevalence of Helicobacter pylori infection in the general adult population of the province of Ourense.

R Macenlle García1, P Gayoso Diz, R A Sueiro Benavides, J Fernández Seara.   

Abstract

OBJECTIVES: to determine the prevalence of Helicobacter pylori infection in the general adult population of the province of Ourense.
MATERIAL AND METHODS: a cross-sectional study was carried out with a randomly selected populational sample. The diagnosis of Helicobacter pylori infection was reached using the 13C-urea breath test.
RESULTS: three hundred and eighty-three subjects were studied, with a prevalence rate of 69.1% (95% CI: 61.7-75.1%); 69.8% (95% CI: 63.2-76.6%) in males and 68.4% (95% CI: 61.5-75.4%) in females (difference not statistically significant). Prevalence increases with age up to a maximum of 88.4% in the 45-54 years age group, and decreases thereafter to a rate of 57.1% in individuals over the age of 84 years.
CONCLUSION: this study reveals that the prevalence rate of Helicobacter pylori infection is high in the general adult population of the province of Ourense. It increases with age until it peaks in the group of middle-aged individuals and is similar in both sexes.

Entities:  

Mesh:

Year:  2006        PMID: 16792453     DOI: 10.4321/s1130-01082006000400003

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  9 in total

Review 1.  Association of Helicobacter pylori with Chronic Kidney Diseases: A Meta-Analysis.

Authors:  Karn Wijarnpreecha; Charat Thongprayoon; Pitchaphon Nissaisorakarn; Veeravich Jaruvongvanich; Kiran Nakkala; Ridhmi Rajapakse; Wisit Cheungpasitporn
Journal:  Dig Dis Sci       Date:  2017-03-06       Impact factor: 3.199

2.  Managing dyspepsia in a primary care setting.

Authors:  A Kenneth Musana; Steven H Yale; Kevin A Lang
Journal:  Clin Med Res       Date:  2006-12

Review 3.  Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease?

Authors:  Ayesha Shah; Nicholas J Talley; Marjorie Walker; Natasha Koloski; Mark Morrison; Daniel Burger; Jane M Andrews; Michael McGuckin; Mike Jones; Gerald Holtmann
Journal:  Dig Dis Sci       Date:  2017-03-09       Impact factor: 3.199

4.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

5.  Gastric cancer mortality trends in Spain, 1976-2005, differences by autonomous region and sex.

Authors:  Esther García-Esquinas; Beatriz Pérez-Gómez; Marina Pollán; Elena Boldo; Pablo Fernández-Navarro; Virginia Lope; Enrique Vidal; Gonzalo López-Abente; Nuria Aragonés
Journal:  BMC Cancer       Date:  2009-09-28       Impact factor: 4.430

Review 6.  Review article: the global emergence of Helicobacter pylori antibiotic resistance.

Authors:  I Thung; H Aramin; V Vavinskaya; S Gupta; J Y Park; S E Crowe; M A Valasek
Journal:  Aliment Pharmacol Ther       Date:  2015-12-23       Impact factor: 8.171

Review 7.  Helicobacter pylori associated factors in the development of gastric cancer with special reference to the early-onset subtype.

Authors:  Małgorzata Pucułek; Julita Machlowska; Ryszard Wierzbicki; Jacek Baj; Ryszard Maciejewski; Robert Sitarz
Journal:  Oncotarget       Date:  2018-07-24

8.  The striking geographical pattern of gastric cancer mortality in Spain: environmental hypotheses revisited.

Authors:  Nuria Aragonés; Beatriz Pérez-Gómez; Marina Pollán; Rebeca Ramis; Enrique Vidal; Virginia Lope; Javier García-Pérez; Elena Boldo; Gonzalo López-Abente
Journal:  BMC Cancer       Date:  2009-09-08       Impact factor: 4.430

9.  Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile.

Authors:  Laura Otth; Myra Wilson; Heriberto Fernández; Carola Otth; Claudio Toledo; Victoria Cárcamo; Paula Rivera; Luis Ruiz
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.